Abstract
We and others recently discovered HHLA2 as a new B7 family member and transmembrane and immunoglobulin domain containing 2 (TMIGD2) as one of its receptors. Based on a new study we propose that HHLA2 may represent a novel immunosuppressive mechanism within the tumor microenvironment and hence could be a target for cancer therapy. TMIGD2 may be another therapeutic target.
Original language | English (US) |
---|---|
Journal | OncoImmunology |
Volume | 4 |
Issue number | 8 |
DOIs | |
State | Published - Aug 3 2015 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2015 Taylor & Francis Group, LLC.
Keywords
- B7 family
- CD28 family
- HHLA2
- TMIGD2
- angiogenesis
- immunosuppression
- immunotherapy
- ligand
- receptor
- tumor microenvironment